Trametinib: a MEK inhibitor for management of metastatic melanoma


This review presents the current data on the efficacy and safety of the selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in patients with metastatic BRAF V600-positive melanoma. The pharmacological, safety, and efficacy data come from the Phase I, II, and III studies of trametinib monotherapy, as well as those in… (More)
DOI: 10.2147/OTT.S72951


5 Figures and Tables